ArticleAlzheimer's research & therapy2026
Reduced serum AHR agonistic activity reflects amyloid dysregulation in AT1 subtypes of Alzheimer's disease.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor linking environmental signals to immune regulation and neurodegeneration. While AHR agonists exert protective effects in Alzheimer’s disease (AD) models, their relevance in humans remains unclear. We investigated AHR agonistic activity in serum and cerebrospinal fluid (CSF) across AT1-defined AD subtypes and its association with amyloid beta (Aβ) metabolism.
methodsWe measured AHR agonistic activity using a luciferase reporter assay in serum and cerebrospinal fluid (CSF) from 138 individuals (113 non-demented, 25 demented) classified by CSF Aβ1-42, Aβ1-42/Aβ1-40 ratio and pTau181 into four AT1 groups: A + T1 + (AD), A + T1- (isolated decrease of Aβ1-42/Aβ1-40 or Aβ1-42), A-T1 + (isolated tau pathology/PASSED), and A-T1- (biomarker-negative controls).
resultsSerum AHR agonistic activity was significantly reduced in biomarker-positive individuals compared to controls (Δ z-score = 2.25, 95% CI [1.33, 3.17], p < 0.001), with the most pronounced reductions observed in two distinct phenotypes: non-demented A-T1 + individuals (z-score = -2.33, 95% CI [-3.26, -1.40]) and A + T1 + patients with preserved CSF Aβ1-42 despite pathological Aβ1-42/Aβ1-40 ratios (p = 0.006 compared to A + T1 + with pathological Aβ1-42). Serum AHR activity correlated negatively with CSF Aβ1-40 (ρ = -0.31, p < 0.001) and Aβ1-42 (ρ = -0.20, p = 0.021) across all participants. The relationship between pTau181 and serum AHR activity showed significant effect modification by amyloidopathy (A) (interaction p < 0.0001): negative in A- individuals (β = -0.54, p < 0.0001) but positive at high pTau181 levels in A + cases (β = 0.12, p = 0.025). CSF AHR activity showed no significant differences between AT1 groups.
conclusionsPeripheral AHR agonistic activity is reduced in early and atypical AD phenotypes and correlates with amyloid peptides Aβ1-42 and Aβ1-40 in CSF. The amyloid status-dependent reversal of pTau181-AHR associations suggests distinct regulatory mechanisms across AT1 groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.